Eosinophil Count Sputum Test in Pakistan at Chughtai Lab

Eosinophil Count (Sputum) at Chughtai Lab

The Eosinophil Count (Sputum) test at Chughtai Lab is a highly specialized, non-invasive laboratory investigation used to measure the percentage of eosinophils in a patient’s sputum. Sputum is the thick mucus produced in the lower respiratory tract—specifically the lungs and bronchial tubes—which is distinct from saliva produced in the mouth. Eosinophils are a specific type of white blood cell (granulocyte) that play a pivotal role in the body’s immune response to allergic reactions, parasitic infections, and chronic airway inflammation. Under normal physiological conditions, eosinophils are present in the airways in very low numbers. However, in response to specific inflammatory triggers, these cells are recruited to the bronchial mucosa, where they release cytotoxic granule proteins, such as major basic protein and eosinophil cationic protein, causing tissue damage, mucus hypersecretion, and airway hyperresponsiveness.

At Chughtai Lab, this diagnostic test is performed using advanced cytological techniques and high-precision microscopy. Sputum cytology is considered the clinical gold standard for directly assessing localized airway inflammation. While systemic markers, such as a complete blood count (CBC) with differential eosinophil levels, provide general systemic information, they often do not correlate perfectly with the active inflammatory processes occurring within the lungs. Therefore, a direct sputum analysis provides pulmonologists, allergists, and immunologists with highly specific, localized diagnostic data. This test is invaluable for phenotyping respiratory diseases like bronchial asthma, monitoring a patient’s response to inhaled corticosteroid (ICS) therapy, and diagnosing complex conditions like non-asthmatic eosinophilic bronchitis (NAEB). By analyzing the cellular composition of the sputum, healthcare providers can transition from empirical treatment to highly personalized, targeted therapeutic strategies, thereby improving patient outcomes and minimizing the side effects of unnecessary medications.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is critical to ensure the collection of a high-quality sputum sample and to prevent contamination with saliva or oral bacteria. Patients are advised to adhere strictly to the following instructions:

• Hydration: Increase fluid intake (especially water) the day before the test. Adequate hydration helps liquefy bronchial secretions, making it easier to mobilize and cough up a deep sputum specimen.
• Fasting: Do not eat or drink anything except water for at least two hours prior to sample collection. This minimizes the risk of food particles contaminating the specimen.
• Oral Hygiene: Immediately before collecting the sample, rinse your mouth thoroughly with water. Do not use commercial mouthwashes, and do not brush your teeth right before the test, as chemical residues or blood from irritated gums can alter the cellular integrity of the sample.
• Medication Guidelines: Continue taking your regularly prescribed respiratory medications, including inhalers, unless specifically instructed otherwise by your prescribing physician. Do not make any changes to your medication regimen without clinical guidance.
• Timing: It is highly recommended to collect the sample early in the morning, as bronchial secretions accumulate in the airways overnight, providing a highly concentrated and diagnostic specimen.

During the Procedure

The collection of sputum can be performed spontaneously or via induction if the patient has difficulty coughing up mucus. The procedure at Chughtai Lab is conducted with the utmost care for patient comfort and safety:

• Spontaneous Collection: The patient is seated comfortably in a well-ventilated area. After performing deep diaphragmatic breathing to loosen secretions, the patient is asked to produce a deep, forceful cough from the chest and expectorate the mucus directly into a sterile, wide-mouthed specimen container.
• Sputum Induction (if required): If a patient cannot produce sputum spontaneously, a trained laboratory professional may perform sputum induction. This involves the inhalation of a nebulized sterile hypertonic saline solution (typically 3% to 5% sodium chloride) over a period of 10 to 20 minutes. The saline irritates the airway lining slightly, stimulating mucus production and coughing. Prior to induction, a short-acting beta-2 agonist (such as salbutamol) is administered via inhaler to prevent transient bronchoconstriction.
• Laboratory Processing: Once collected, the sample is immediately sent to the pathology department. A laboratory technologist treats the sputum with a mucolytic agent, such as dithiothreitol (DTT), to disperse the cells. The sample is then centrifuged, and the cellular pellet is smeared onto glass slides.
• Staining and Evaluation: The slides are stained using specialized dyes, such as Wright-Giemsa or Hansel stain, which highlight the characteristic bilobed nuclei and bright reddish-orange granules of eosinophils. A consultant pathologist or cytotechnologist examines the slides under a high-power microscope, counting a minimum of 400 inflammatory cells to determine the exact percentage of eosinophils relative to other inflammatory cells (such as neutrophils, macrophages, and lymphocytes).
• Safety and Experience: Spontaneous collection is completely non-invasive and carries no risks. Sputum induction is generally safe but may cause mild coughing, throat irritation, or transient wheezing, which is closely monitored and managed by the clinical staff.

When is an Eosinophil Count (Sputum) Performed?

Diagnosis and Phenotyping of Bronchial Asthma

Bronchial asthma is a highly heterogeneous inflammatory airway disease with diverse underlying pathophysiological mechanisms, known as phenotypes. A sputum eosinophil count is performed to identify the eosinophilic asthma phenotype, which is characterized by a sputum eosinophil level of 3% or greater. Identifying this specific phenotype is clinically crucial because patients with eosinophilic asthma exhibit a highly favorable therapeutic response to inhaled corticosteroids (ICS) and targeted monoclonal antibody therapies (such as anti-IL-5 or anti-IL-5 receptor biologics). Conversely, patients with non-eosinophilic asthma (such as neutrophilic or paucigranulocytic asthma) do not respond as effectively to high-dose steroids and require alternative therapeutic pathways. This test allows physicians to tailor asthma management precisely to the patient’s biological profile.

Monitoring and Titrating Corticosteroid Therapy

In patients with severe or refractory asthma, managing airway inflammation can be challenging. Physicians frequently request a sputum eosinophil count to monitor the efficacy of ongoing anti-inflammatory treatments. If a patient’s sputum eosinophil count remains elevated despite high-dose inhaled or oral corticosteroids, it suggests persistent, uncontrolled airway inflammation. This clinical finding helps physicians distinguish between steroid-resistant asthma, poor patient adherence to medication, incorrect inhaler technique, or the need for add-on biologic therapies. Conversely, a low sputum eosinophil count (less than 1% to 2%) indicates well-controlled inflammation, allowing the clinician to safely step down the steroid dose, thereby minimizing the risk of long-term corticosteroid-induced side effects.

Investigation of Chronic Unexplained Cough

A chronic cough lasting longer than eight weeks with a normal chest X-ray presents a significant diagnostic challenge. A sputum eosinophil count is a vital diagnostic tool in evaluating such cases, particularly to confirm or rule out Non-Asthmatic Eosinophilic Bronchitis (NAEB). Patients with NAEB present with a chronic, often dry cough and demonstrate sputum eosinophilia (>3%), but unlike classic asthmatics, they do not exhibit airway hyperresponsiveness or variable airflow limitation on spirometry. Because NAEB does not respond to standard cough suppressants or bronchodilators but resolves completely with inhaled corticosteroids, performing a sputum eosinophil count prevents diagnostic delays and ensures the patient receives the correct, highly effective treatment promptly.

Differentiation Between Asthma and COPD

Distinguishing between bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) can be difficult, especially in older adults, smokers, or patients with long-standing respiratory symptoms who may exhibit features of both conditions—a clinical scenario known as Asthma-COPD Overlap (ACO). While classic COPD is primarily characterized by neutrophilic airway inflammation driven by cigarette smoke or environmental toxins, a subset of COPD patients displays significant eosinophilic airway inflammation. A sputum eosinophil count helps clinicians identify this specific subset of COPD patients. Those with elevated sputum eosinophils are much more likely to experience frequent exacerbations but also show a significantly better response to inhaled corticosteroids compared to those with purely neutrophilic inflammation.

Assessment of Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis (ABPA) is an intense hypersensitivity reaction to the colonization of the airways by the fungus Aspergillus fumigatus, occurring almost exclusively in patients with asthma or cystic fibrosis. A sputum eosinophil count is performed as part of the diagnostic workup for suspected ABPA. The disease is characterized by severe, eosinophil-rich airway inflammation, which leads to bronchiectasis and recurrent pulmonary infiltrates. Detecting marked sputum eosinophilia, often accompanied by fungal hyphae and characteristic cellular breakdown products under the microscope, helps confirm the diagnosis and guides the initiation of systemic corticosteroids and antifungal medications to prevent permanent lung damage.

What Does an Eosinophil Count (Sputum) Detect?

The microscopic analysis of a sputum sample at Chughtai Lab provides a comprehensive cytological profile of the lower respiratory tract. This test can detect a wide range of normal and pathological findings, including:

• Normal Eosinophil Levels: A percentage of eosinophils below 1% to 3% of total inflammatory cells, indicating the absence of active eosinophilic airway inflammation.
• Mild Sputum Eosinophilia: Eosinophil levels between 3% and 5%, suggesting low-grade allergic or eosinophilic airway inflammation.
• Moderate Sputum Eosinophilia: Eosinophil levels between 5% and 10%, indicating active, symptomatic eosinophilic asthma or allergic respiratory disease.
• Severe Sputum Eosinophilia: Eosinophil levels exceeding 10%, representing intense, uncontrolled airway inflammation, often seen in severe asthma exacerbations or systemic eosinophilic disorders.
• Charcot-Leyden Crystals: Slender, bipyramidal microscopic crystals composed of galectin-10 (an eosinophil cell membrane protein), indicating extensive eosinophil degranulation and severe allergic inflammation.
• Curschmann’s Spirals: Coiled, spiral-shaped mucus plugs derived from the small bronchioles, commonly observed in patients with bronchial asthma and chronic bronchitis.
• Creola Bodies: Compact clusters of desquamated ciliated columnar bronchial epithelial cells, indicating significant physical damage to the airway lining.
• Sputum Neutrophilia: An elevated percentage of neutrophils (typically >60-80%), indicating active bacterial infection, chronic bronchitis, or neutrophilic asthma.
• Alveolar Macrophages: Large mononuclear phagocytes originating from the deep alveoli; their presence confirms that the specimen is a true lower respiratory tract sample and not merely saliva.
• Squamous Epithelial Cells: Cells originating from the oral cavity; a high percentage (>10%) indicates significant salivary contamination, rendering the specimen inadequate for accurate diagnostic interpretation.
• Bronchial Epithelial Cells: Individual ciliated or goblet cells from the bronchial lining, indicating mucosal shedding or irritation.
• Sputum Lymphocytosis: An increased percentage of lymphocytes, which can be associated with viral respiratory infections, hypersensitivity pneumonitis, or sarcoidosis.
• Plasma Cells: Antibody-producing cells that may be present in chronic inflammatory conditions of the respiratory tract.
• Bacterial Pathogens: Microscopic visualization of pathogenic bacteria (such as Streptococcus pneumoniae or Haemophilus influenzae), suggesting secondary bacterial bronchitis or pneumonia.
• Fungal Hyphae or Spores: Microscopic structures of fungi, such as Aspergillus species, indicating fungal colonization, infection, or allergic bronchopulmonary aspergillosis.
• Acellular Mucus Debris: The baseline mucin protein matrix of sputum, which may appear dense or inspissated in obstructive airway diseases.
• Elastic Fibers: Fragmented fibers indicating destructive lung pathology, such as bronchiectasis, lung abscess, or necrotizing pneumonia.
• Erythrocytes (Red Blood Cells): The presence of red blood cells, indicating micro-hemorrhage, severe mucosal inflammation, or trauma from intense coughing.
• Dust Cells: Alveolar macrophages containing phagocytosed carbon or smoke particles, commonly found in smokers or individuals exposed to high levels of air pollution.
• Goblet Cell Hyperplasia: An increased number of mucus-secreting goblet cells, indicative of chronic mucus hypersecretion.
• Lecithin-Cholesterol Crystals: Microscopic crystals occasionally observed in chronic, destructive pulmonary conditions or chronic abscesses.
• Atypical or Dysplastic Cells: Cells showing abnormal nuclear or cytoplasmic features, which may warrant further cytological investigation to rule out respiratory tract malignancies.
• Normal Cellular Distribution: A balanced cytological profile dominated by healthy alveolar macrophages and minimal inflammatory cells, confirming healthy airway mucosal status.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing rapid, highly accurate diagnostic results to facilitate timely clinical decision-making. Because the Eosinophil Count (Sputum) is a specialized cytological investigation requiring meticulous laboratory processing, staining, and expert microscopic evaluation by a consultant pathologist, the turnaround time is typically 24 to 48 hours from the time of sample collection.

As soon as the diagnostic report is finalized and signed off by the pathologist, patients receive an automated SMS notification on their registered mobile number. Chughtai Lab offers multiple convenient methods to access and download reports. Patients can view and download their reports digitally via the official Chughtai Lab website by entering their patient ID and password, or through the user-friendly Chughtai Lab Mobile App, available on both iOS and Android platforms. For those who prefer physical copies, printed reports can be collected directly from any Chughtai Lab collection center located across Pakistan.

Eosinophil Count (Sputum) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Eosinophils (%)	< 3% of total inflammatory cells	≥ 3% (Eosinophilic asthma, non-asthmatic eosinophilic bronchitis, ABPA)
Neutrophils (%)	Predominant cell type in healthy non-smokers (typically 50% to 80%)	Significantly elevated (> 80%), indicating bacterial infection, COPD, or neutrophilic asthma
Alveolar Macrophages	Present in moderate to high numbers	Absent or extremely low (suggests salivary contamination and an invalid specimen)
Squamous Epithelial Cells	Minimal to absent (< 10%)	Elevated (> 10%), indicating salivary contamination; sample recollecting may be required
Charcot-Leyden Crystals	Absent	Present, indicating active eosinophil degranulation and severe allergic airway disease
Curschmann’s Spirals	Absent	Present, indicating mucus plugging and obstructive airway diseases like asthma
Creola Bodies	Absent	Present, indicating severe bronchial epithelial shedding and airway damage
Microorganisms	None or normal oral flora	Pathogenic bacteria or fungal hyphae (e.g., Aspergillus), indicating active infection or colonization

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Eosinophil Count (Sputum)?

• Experienced Healthcare Professionals: Chughtai Lab employs highly qualified consultant pathologists and cytotechnologists specializing in respiratory cytology, ensuring accurate identification and counting of cellular structures.
• Patient-Focused Care: The laboratory staff is trained to guide patients through the sputum collection process with empathy, professionalism, and clear instructions to ensure a comfortable experience.
• Quality Diagnostic Services: Chughtai Lab adheres to strict international quality control standards, participating in external quality assurance programs to maintain diagnostic precision.
• Professional Reporting: Reports are detailed, structured, and include key cytological parameters and reference ranges to assist clinicians in making informed treatment decisions.
• Modern Diagnostic Approach: Utilizing state-of-the-art microscopes, advanced staining techniques, and standardized processing protocols to deliver reliable results.
• Comfortable Environment: All collection centers are designed to provide a clean, hygienic, and comfortable environment for patients during sample collection or induction.
• Convenient Location: With an extensive network of collection centers across Pakistan, patients can access high-quality diagnostic services close to home.
• Commitment to Accurate Diagnosis: Chughtai Lab is dedicated to providing timely, precise, and evidence-based diagnostic insights, supporting patients and physicians throughout the diagnostic journey.